Context: Anorexia nervosa (AN) is associated with severe metabolic and endocrine alterations, including growth hormone (GH) resistance and reduced insulin-like growth factor 1 (IGF-1). The longitudinal behavior of IGF-1 during treatment remains incompletely characterized. Objective: To evaluate IGF-1 levels in current and weight-restored AN, determine metabolic correlates, and examine longitudinal changes during clinical treatment. Design: Cross-sectional analysis in a population-based cohort and longitudinal analysis in a clinical cohort. Setting: UK Biobank (UKB) and a specialist eating disorder clinic. Participants: (1) UKB: 129 adult women with current AN, 2380 weight-restored AN, and 2380 healthy controls (HC) matched for age, sex, and body mass index (BMI). (2) Clinical cohort: 189 adult women with AN assessed at baseline and 12-month follow-up. Main outcome measures: Plasma IGF-1 levels; secondary metabolic and reproductive hormones, including GH, insulin, glucose, free triiodothyronine (FT3), and gonadal hormones. Results: Across the UKB groups, IGF-1 levels showed a graded pattern: lowest in current AN, medium in weight-restored AN, and highest in HC. In the clinical cohort, IGF-1 correlated positively with insulin, glucose, and FT3, and negatively with GH, consistent with GH resistance. IGF-1 levels increased significantly over 12 months of treatment (P = .003), with higher BMI at baseline predicting greater increases. Higher IGF-1 levels were associated with a greater likelihood of menstrual function independent of BMI (P < .001). Conclusion: IGF-1 appears reduced in current AN and may only partly normalize with weight restoration. IGF-1 may reflect metabolic state and reproductive function, suggesting value as an indicator of severity and treatment response.